Search clinical trials for: cetuximab

Total 1010 results

Wangxia LV

Recruiting

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Colorectal Cancer Metastatic

China
M.D. Anderson Cancer Center

Not yet recruiting

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Peking University People's Hospital
Peking University Shougang Hospital; Shandong Cancer Hospital and Institute

Recruiting

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Ewing Sarcoma

China
Fulgent Pharma LLC.

Recruiting

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

United States
Gruppo Oncologico del Nord-Ovest

Recruiting

Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients (HAITI)

Colorectal Cancer Metastatic

Italy
Hansoh BioMedical R&D Company

Not yet recruiting

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Advanced Solid Tumor
Beijing Hospital
Bethune Charitable Foundation

Recruiting

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Metastatic Colorectal Cancer | MSS | RAS Mutation

China
Qilu Hospital of Shandong University

Recruiting

Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer

Colon Cancer

China
Shanghai Henlius Biotech

Not yet recruiting

A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects

EGFR Overexpression
Jiang Feng

Recruiting

Neoadjuvant SBRT in Localized Advanced HNSCC

Head and Neck Squamous Carcinoma

China
Xinqiao Hospital of Chongqing
Chongqing Medical University

Not yet recruiting

Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Biond Biologics

Not yet recruiting

A Study of BND-35 in Participants With Advanced Solid Tumors

Cancer

Israel
Fate Therapeutics

Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Advanced Solid Tumor

United States
Glenn J. Hanna
ImmunityBio, Inc.

Recruiting

PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
The First Affiliated Hospital of Zhengzhou University

Recruiting

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

Metastatic Colorectal Cancer

China
Quanta Therapeutics

Recruiting

QTX3034 in Patients With KRAS G12D Mutation

Solid Tumors

United States
City Clinical Oncology Hospital No 1
Atlas Biomed; N.N. Blokhin National Medical Research Center of Oncology; Moscow...

Recruiting

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer (CRC01)

Colorectal Neoplasms | Chemotherapy Effect | Molecular Sequence Variation

Russian Federation
Shanghai Zhongshan Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Spanish Cooperative Group for the Treatment of...
Merck, S.L., Spain; Pierre Fabre Ibérica, S.A.

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer (CEBBRA)

Colorectal Cancer
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
Shanghai Institute Of Biological Products

Not yet recruiting

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Incyte Corporation

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Solid Tumors

United States, France, Italy, Australia, Spain, Canada, Belgium
Eye & ENT Hospital of Fudan University

Not yet recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Locally Advanced Hypopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab (COSTIC)

Metastatic Colorectal Cancer | Cetuximab | Skin Toxicity

China
Xuekui Liu

Not yet recruiting

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma (CZCNRHNSCC)

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable

China
University of Turin, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Recruiting

Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules (RECOGNISE)

Lung Cancer | EGFR | Cetuximab | Video-assisted Thoracic Surgery

Italy
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
First Affiliated Hospital of Zhejiang University

Recruiting

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Squamous Cell Carcinoma of Head and Neck

China
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia
Tang-Du Hospital

Not yet recruiting

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

Rectal Cancer
Roswell Park Cancer Institute

Recruiting

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Colo-rectal Cancer

United States
Shanghai Kechow Pharma, Inc.

Not yet recruiting

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Colorectal Cancer Metastatic
University of Chicago

Not yet recruiting

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

HPV-Negative Squamous Cell Carcinoma

United States
Wuhan Union Hospital, China

Not yet recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC (PC-1)

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy

China
M.D. Anderson Cancer Center
Eli Lilly and Company; BioMed Valley Discoveries, Inc

Recruiting

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Metastatic Colorectal Cancer

United States
Zhejiang Cancer Hospital

Not yet recruiting

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

Metastatic Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (CEIL)

Metastatic Colorectal Cancer

China
Deciphera Pharmaceuticals LLC
Pfizer

Recruiting

A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Colorectal Cancer | GIST

United States
University of Miami

Recruiting

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Glioblastoma Multiforme | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | DIPG Brain Tumor | H3 K27M | Fibrillary Astrocytomas | Diffuse Intrinsic Brainstem Glioma

United States
Genentech, Inc.

Recruiting

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Colorectal Cancer | Non-Small Cell Lung Cancer

Korea, Republic of, Australia, United States
Fudan University

Not yet recruiting

Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Colorectal Cancer | Liver Metastases

China
Groupe Oncologie Radiotherapie Tete et Cou

Recruiting

Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01)

Squamous Cell Carcinoma of the Head and Neck

France
University Medical Center Groningen

Recruiting

Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid) (MIRROR)

Glioblastoma | High-grade Glioma

Netherlands
Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Australia, Singapore
Fudan University

Not yet recruiting

Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

Colorectal Cancer Liver Metastases

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Recruiting

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck

United States

3

Subscribe